We've been pushing the state of the art on how you do AI and machine learning on high-velocity data,' FogHorn CEO David King tells CRN about the startup's edge intelligence capabilities.

Foghorn Therapeutics Inc. announced continued enrollment in its Phase 1 trial for FHD-909, a first-in-class oral selective SMARCA2 inhibitor targeting SMARCA4 mutated cancers, particularly non ...